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Dendritic polyglycerol sulfate as a novel platform
for paclitaxel delivery: pitfalls of ester linkage†
Ana Sousa-Herves,‡a Patrick Würfel,‡b Nicole Wegner,b Jayant Khandare,a,c
Kai Licha,b Rainer Haag,a Pia Welker*b and Marcelo Calderón*a
In this study, dendritic polyglycerol sulfate (dPGS) is evaluated as a delivery platform for the anticancer,
tubulin-binding drug paclitaxel (PTX). The conjugation of PTX to dPGS is conducted via a labile ester
linkage. A non-sulfated dendritic polyglycerol (dPG) is used as a control, and the labeling with an indo-
carbocyanine dye (ICC) renders multifunctional conjugates that can be monitored by ﬂuorescence
microscopy. The conjugates are characterized by 1H NMR, UV-vis measurements, and RP-HPLC. In vitro
cytotoxicity of PTX and dendritic conjugates is evaluated using A549 and A431 cell lines, showing a
reduced cytotoxic eﬃcacy of the conjugates compared to PTX. The study of uptake kinetics reveals a
linear, non saturable uptake in tumor cells for dPGS-PTX-ICC, while dPG-PTX-ICC is hardly taken up.
Despite the marginal uptake of dPG-PTX-ICC, it prompts tubulin polymerization to a comparable extent
as PTX. These observations suggest a fast ester hydrolysis and premature drug release, as conﬁrmed by
HPLC measurements in the presence of plasma enzymes.
Introduction
Paclitaxel (PTX)1 is a commonly used chemotherapeutic of low
molecular weight which binds to α- and β-tubulin.2–4 PTX pro-
motes tubulin polymerization and formation of highly stable
microtubules, which disrupt the normal tubule dynamics
required for cellular division therefore causing cell apoptosis.5
The mode of action of PTX can be visualized by imaging
tubulin showing an altered intracellular distribution after
incubation with the drug. Despite the wide use of PTX in
various carcinomas, such as ovarian and non-small cell lung
cancers,6,7 it presents several limitations. PTX is poorly soluble
in water and therefore has to be administered with Cremophor
EL® and ethanol vehicles, which results in pharmacologic pro-
blems and side eﬀects.8–11
Macromolecular conjugates, such as those based on poly-
meric scaﬀolds, are ideal entities for the delivery of cytotoxic
drugs or diagnostic agents. In particular, polymer thera-
peutics, i.e. polymeric prodrugs, polymer conjugates of pro-
teins, drugs and aptamers, have been widely employed during
the last decades to increase the solubility and improve the
body distribution and cellular uptake of therapeutic
agents.12–17 Moreover, after specific accumulation in the tar-
geted tissue or organ, the cytotoxic drug can be released in a
controlled fashion by the eﬀect of internal or external stimuli,
leading to an optimization of the therapy. One of the most well-
known polymer therapeutics formulations is Opaxio™, currently
in phase III for the treatment of ovarian cancer. This polymer
therapeutic has a very high drug loading, presents prolonged cir-
culation times in the bloodstream, and can be subsequently
accumulated in tumors where PTX is eﬀectively released.18–21
Opaxio™ results from the attachment of PTX to polyglutamic
acid through ester linkages, a commonly employed strategy to
covalently modify PTX with macromolecules.22–28
Multivalent dendritic polymers constitute a very appealing
platform for the preparation of polymer therapeutics. The
highly branched, globular architecture of these molecules
gives rise to a number of interesting properties when com-
pared to linear polymers of analogous molecular weight. In
addition, their surface multifunctionality allows the simul-
taneous incorporation of drugs, imaging agents, or targeting
moieties.15,29,30 Dendritic structures based on highly bio-
compatible polyglycerol (dPG) are ideal architectures for anti-
cancer therapy purposes, because they are water-soluble, can
be tuned in size, easily functionalized, and provide multi-
valently arranged ligands on the surface.31–33 Particularly inter-
esting is dendritic polyglycerol sulfate (dPGS), a highly anionic
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dendritic polymer which has shown an exceptionally high anti-
inflammatory potential due to a high aﬃnity binding to
L-selectin.34–36 dPGS has not shown any cytotoxic side eﬀects in
vitro and in vivo35,37 and can be easily synthesized on a kilogram
scale and in a broad range of sulfation degrees and molecular
weights.38,39 In addition, dPGS has demonstrated eﬃcient
in vivo anti-inflammatory eﬃcacy (mouse dermatitis model)35
and could be used for in vivo molecular imaging of inflamma-
tory diseases after labeling with a near infrared (NIR) dye.40,41
On the basis of the inflammation-targeting properties of
dPGS, we envisioned the preparation of dPGS-PTX conjugates
as novel anti-cancer agents with potential self-targeting pro-
perties in inflammation-related carcinoma processes. Herein,
we present the synthesis of such water-soluble conjugates,
their modification with an imaging agent (indocarbocyanine
dye, ICC), and the evaluation of their in vitro cellular uptake
and activity towards tubulin polymerization (Fig. 1). As a non-
targeting control, a non-sulfated, neutral dPG-PTX conjugate
was synthesized and compared in vitro with its sulfated
counterpart. For the conjugation of PTX to dPG and dPGS we
have selected a labile ester linkage, so that PTX release could
be triggered by the low pH typically found in the lysosomes
and/or by the action of esterases. We have analyzed the PTX
release from both conjugates by HPLC at diﬀerent pHs and in
the presence of human plasma. The obtained drug release pro-
files, together with the in vitro activity observed for PTX,
suggest that PTX is released extremely fast in the presence of
hydrolytic conditions or esterases. This observation implies
that the selection of ester linkages for the covalent attachment
of PTX or other cytotoxic drugs to polymeric platforms should
be carefully evaluated for each particular system.
Experimental
Materials and methods
Chemicals and reagents were obtained from Acros Organics,
Sigma-Aldrich, and Merck. They were reagent grade and used
as received unless otherwise stated. Milli-Q water was prepared
using a Millipore water purification system. Dry reactions were
performed in flame-dried glassware under argon atmosphere.
Purification by dialysis was performed with membranes of
benzoylated cellulose or regenerated cellulose (MWCO 2000;
Sigma-Aldrich). Size exclusion chromatography was performed
with Sephadex G-25 superfine (GE Healthcare) under ambient
pressure and temperature. Reversed phase chromatographic
purification was performed using RP-18 Redisep flash
columns (ISCO CombiFlash Rf system). Dendritic polyglycerol
(dPG, Mn ≈ 6 kDa, PDI < 1.6) was prepared according to litera-
ture via an anionic multibranching ring-opening polymeriz-
ation of glycidol and pentaerythritol as starter.42,43
2S-ICC-NHS and 2S-ICC-NH2 were obtained from mivenion
GmbH (Berlin, Germany).44 1H NMR spectra were recorded on
a Jeol ECX 400, Bruker AMX 500, or on a Bruker BioSpin AV
700 spectrometer. Chemical shifts are reported in ppm
(δ units) downfield from internal tetramethylsilane (for
CDCl3), the HOD solvent peak (for D2O), or residual solvent
peak [deuterated dimethyl sulfoxide (DMSO-d6)]. For ESI
measurements, a TSQ 7000 (Finnigan Mat) instrument was
used. Elemental analysis was performed on a Vario EL III
elemental analyzer using sulfanilic acid as standard. Absorp-
tion spectra were recorded on a LAMBDA 950 UV/Vis/NIR
spectrometer (PerkinElmer, USA). Single human plasma was
obtained from a healthy consented unmedicated donor
according to German ethical issues. Cell culture experiments
were done under sterile conditions. A549 lung-carcinoma
cells45 were purchased from DSMZ, Braunschweig. Cells were
cultivated with Dulbecco’s Modified Eagle Medium (DMEM),
supplemented with 10% fetal calf serum (FCS) and 1% Penicil-
lin/Streptomycin. Subcultivation was done twice a week using
trypsin/ethylenediaminetetraacetic acid (EDTA) in a ratio of
1 : 10. Vulva-carcinoma A431 cells45 were provided by
Dr. J. Dernedde (Charité Universitätsmedizin Berlin, Germany)
and cultivated as A549 cells but with a subcultivation ratio of
1 : 12–16.
Synthesis and characterization
The dendritic conjugates employed in this work are summar-
ized in Table 1.
dPGS amine (1). Dendritic polyglycerol sulfate (Mn ≈
13 kDa) containing NH2 groups was prepared following a
slightly modified procedure recently reported by our group.46
In brief, dendritic polyglycerol (Mn ≈ 6 kDa) was partially
mesylated and the resulting mesyl groups were subsequently
substituted for azides by treatment with NaN3. After sulfation
with SO3 pyridine complex in N,N-dimethylformamide (DMF),
the azide groups were reduced under aqueous conditions with
tris(2-carboxyethyl)phosphine (TCEP) to yield dPGS amine (1)
with free amino functionalities available for further conju-
gation. After extensive purification by dialysis, the sulfur
content was determined by elemental analysis and corres-
ponded with a degree of sulfation of 80%.
PTX-Suc-NHS ester (2). Paclitaxel (25.0 mg, 0.029 mmol)
and succinic anhydride (29.3 mg, 0.29 mmol) were dissolved
in dry pyridine (2.1 mL) under argon atmosphere. The mixture
was stirred at room temperature (rt) for 24 h protected from
light. The reaction was monitored by TLC [silica plates,
CHCl2–MeOH (10 : 1)] until no free PTX was observed. After
Fig. 1 Idealized chemical structure of multifunctional dPGS conjugated
to PTX and ICC (dPGS-PTX-ICC (5)).
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solvent evaporation, PTX-succinate could be isolated by pre-
cipitation with H2O. After extensive washing of the precipitate,
the product was redissolved in CHCl2–MeOH and concentrated
under vacuum to yield 2′-hemisuccinate derivative of paclitaxel
as a white solid (27.4 mg, 99%). 1H NMR (500 MHz, CDCl3)
and ESI-MS were consistent with previously reported
results.25,26 Subsequently, PTX-hemisuccinate (18 mg,
0.019 mmol) was dissolved in freshly distilled EtOAc (500 µL)
under Ar atmosphere. N-hydroxysuccinimide (NHS, 2.46 mg,
0.021 mmol) and N,N′-dicyclohexylcarbodiimide (DCC,
4.33 mg, 0.021 mmol) were added to the solution and the
mixture was stirred at rt for 48 h. TLC in CHCl2–MeOH (10 : 1)
was used to monitor the reaction progress. After filtration to
remove insoluble ureas, the solvent was evaporated under
reduced pressure yielding 2 as a white solid (14.7 mg, 75%).
1H NMR (500 MHz, CDCl3, δ): 8.14 (2H), 7.70 (2H), 7.54 (1H),
7.47–7.23 (10H), 7.10 (1H), 6.23 (1H), 6.17 (1H), 5.93 (1H), 5.63
(1H), 5.47 (1H), 4.96 (1H), 4.38 (1H), 4.24 (1H), 4.13 (1H), 3.74
(1H), 2.91–2.72 (4H), 2.66 (1H), 2.68–2.44 (4H), 2.37 (3H), 2.36
(2H), 2.16 (3H), 1.98 (1H), 1.85 (4H), 1.62 (3H), 1.17 (3H), 1.07
(3H). 13C NMR (125 MHz, CDCl3, δ): 203.95, 171.26, 169.96,
169.14, 168.15, 168.12, 167.84, 167.41, 166.96, 142.78, 133.86,
133.69, 132.79, 132.73, 131.91, 131.79, 130.29, 129.29, 129.09,
128.82, 128.60, 128.56, 128.49, 127.33, 126.83, 84.50, 81.06,
79.01, 76.50, 75.66, 75.08, 74.73, 72.14, 72.03, 58.52, 52.90,
45.59, 43.20, 35.53, 33.46, 31.21, 26.81, 26.22, 25.45, 24.78,
22.68, 22.14, 20.88, 14.81, 9.69. ESI-MS m/z: [M + Na]+ calcd for
C55H58N2O19Na, 1073; found, 1073. (Fig. S1, ESI†).
dPGS-PTX (3). PTX-Suc-NHS (2) (7 mg, 0.0067 mmol) and
dPGS amine (1) (45.2 mg, 0.0023 mmol) were dissolved in a
mixture of DMF–H2O (9 : 1) (2.21 mL). After 48 h under mag-
netic stirring at rt, the crude product was purified by dialysis
first against acetone–Milli-Q water (1 : 1) and then against
Milli-Q water. After freeze-drying, 37.4 mg (80%) of dPGS-PTX
conjugate (3) were obtained. 1H NMR spectra in DMSO-d6–
D2O–DCl (85 : 13.5 : 1.5, v/v) showed that the conjugate con-
tains approx. 1.4 mol of PTX per mol of dPGS (Fig. S2, ESI†).
1H NMR, [700 MHz, DMSO-d6–D2O–DCl, δ]: 7.90–7.30 (15H),
7.10 (1H), 6.24 (2H), 6.17 (1H), 5.93 (1H), 5.63 (1H), 5.47 (1H),
4.11–3.08 (405H), 2.37 (3H), 2.16 (3H), 1.85 (4H), 1.62 (3H),
1.07 (6H).
dPG-PTX (4). PTX-Suc-NHS (2) (11.8 mg, 0.0113 mmol) and
dPG amine37 (22.6 mg, 3.76 mmol) were dissolved in a mixture
of DMF–H2O (9 : 1) (2.21 mL). After 48 h under magnetic
stirring at rt, the crude product was purified by dialysis first
against acetone–Milli-Q water (1 : 1) and then against Milli-Q
water. After freeze-drying, 23.7 mg (90%) of dPG-PTX conjugate
(4) were obtained. 1H NMR spectrum DMSO-d6 showed that
the compound has about 1 mol of Paclitaxel per mol of dPG.
1H NMR (700 MHz, DMSO-d6, δ): 8.05–7.34 (15H), 7.01 (1H),
6.50 (2H), 6.30 (1H), 6.03 (1H), 5.43 (1H), 3.90–3.07 (405H),
2.23 (3H), 2.11 (3H), 2.02 (4H), 1.79 (3H), 1.26 (6H).
dPGS-PTX-ICC (5) and dPG-PTX-ICC (6). 3 and 4 (2.5 mg,
0.17 and 0.40 mmol, respectively) were separately dissolved in
0.3 mL 90% DMF aqueous solution. 2S-ICC-NHS dye (0.4 mg,
0.51 mmol for 3; 0.76 mg, 1.2 mmol for 4) was dissolved in
0.1 mL of DMF and added to the solutions in the presence of
N,N-diisopropylethylamine (DIPEA, 0.51 mmol and 1.2 mmol,
respectively). Reaction mixtures were stirred for 72 h at 41 °C.
The reactions were purified by gel-filtration through a Sepha-
dex G-25 column with Milli-Q water. After freeze-drying, 5 and
6 were obtained as pink powders (2.3 and 2.5 mg respectively,
99%). The conjugates were analyzed by UV-vis spectroscopy,
which showed that the average molar dye-to-polymer ratio was
0.2 in both cases (extinction coeﬃcient of ICC at 550 nm =
120 000 cm−1 M−1).
dPGS-ICC (7) and PTX-ICC (8). dPGS-ICC (7) was prepared
as previously reported.38 For the synthesis of PTX-ICC (8), PTX
(20 mg, 0.021 mmol), N,N,N′,N′-tetramethyl-O-(1H-benzotriazol-
1-yl)uronium hexafluorophosphate (HBTU, 10.34 mg, 0.027
mmol), and DIPEA (9.6 μL, 0.056 mmol) were dissolved in DMF
(0.5 mL). After 45 min stirring under argon at rt, 2S-ICC-NH2
dye (22.81 mg, 0.027 mmol) and DIPEA were added (4.8 μL,
0.028 mmol). The mixture was allowed to react for further 48 h
and then the solvent was evaporated under vacuum. TLC in
CHCl2–MeOH (1 : 1) was used to monitor the reaction progress.
Purification was achieved by RP-18 chromatography (Combi-
Flash) using MeOH as eluent. After solvent evaporation 8
(15 mg, 43%) was obtained as a pink solid. MS m/z: [M + Na]+
calcd for C86H100O23S2N5Na2, 1680; found, 1680.
Kinetics of in vitro cellular uptake and elimination
For quantitative cellular uptake kinetics, A431 cells (2.5 × 105
cells per well) were grown in 24-well plates overnight. Sub-
sequently, 1 µM dPGS-PTX-ICC (5), dPG-PTX-ICC (6) and the
controls dPGS-ICC (7) and PTX-ICC (8) were diluted in DMEM
and incubated for diﬀerent time intervals (17 measurement
points). After incubation, the medium was removed, the cells
rinsed with cold phosphate buﬀered saline (PBS) and har-
vested with trypsin/EDTA. After further PBS rinsing and cen-
Table 1 Summary and properties of described dendritic conjugates
Compound Theor. molecular weight Surface charge Conjugated PTX (molar ratio)a Conjugated ICC (molar ratio)b
dPGS-PTX (3) ≈14.2 kDa Negative ≈1.4 PTX/dPGS —
dPG-PTX (4) ≈6.2 kDa Neutral ≈1.0 PTX/dPG —
dPGS-PTX-ICC (5) ≈14.3 kDa Negative ≈1.4 PTX/dPGS 0.2 ICC/dPGS
dPG-PTX-ICC (6) ≈6.8 kDa Neutral ≈1.0 PTX/dPG 0.2 ICC/dPG
dPGS-ICC (7) ≈13.3 kDa Negative — 0.4 ICC/dPGS
aDetermined by 1H NMR. bDetermined by UV-vis (λ = 550 nm).
Nanoscale Paper






























































































trifugation (250g, 8 °C), the supernatant was discarded and the
cells resuspended in a 3% FCS/PBS solution. Measurements
were done in duplicate for each measurement point with a
fluorescence-activated cell sorting (FACS) Calibur-Cytometer at
the Channel FL2-H using CellQuest Pro 4.0.2 (ICC: λex = 515/
550, λem = 570 nm). The experiment was replicated once. For
elimination kinetics, A431 cells (2 × 105 cells per well) were
grown in 24-well plates overnight. After incubation of 1 µM of
dPGS-ICC (7) and dPGS-PTX-ICC (5) diluted in DMEM for 24 h,
the cell medium was completely removed and the cells washed
with warm PBS and incubated with drug free DMEM again.
Subsequently, the cells were washed and harvested with
trypsin/EDTA at diﬀerent time intervals (up to 48 h). After
rinsing with PBS and centrifugation (350g, 6 °C), the cells were
resuspended in 3% FCS/PBS and analyzed by a FACS Calibur-
Cytometer using CellQuest Pro 4.0.2. Measurements were done
in triplicate for every measurement point and replicated once.
In vitro cytotoxicity
For concentration-response curves, A549 and A431 cells were
seeded in 96-well plates in 100 µL of medium (0.8–3.5 × 103
cells per well). After attaching overnight, 50 µL were removed
and substituted with fresh medium containing diﬀerent con-
centrations of PTX or dPGS-PTX (3), dissolved in sup-
plemented medium, and incubated for 24, 48, and 72 h. 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay was used for viability measurements. Briefly, after incu-
bation periods, 10 µL of MTT solution were added and incu-
bated for another 4 h. Subsequently, 50 µL of medium were
removed and 150 µL of a 0.04 N HCl/2-propanol solution were
added. After dissolving the formazan products, optical density
was measured at λ1 = 570 nm and λ2 = 620 nm (reference filter)
with a microplate reader (anthos htII). Each concentration was
pipetted six times; the experiment was replicated at least
thrice. To evaluate the cytotoxicity of dPGS amine (1) and
dPG-PTX (4), A431 were seeded in 96-well plates (2.5 × 103 cells
per well). After attaching for 4 h, dPGS amine (1), dPGS-PTX
(3), PTX and dPG-PTX (4) were diluted in DMEM and incu-
bated for 48 h. MTT assays were subsequently performed. The
experiment was repeated at least thrice. Calculation of half
maximal inhibitory concentrations (IC50) values was done with
GraphPad Prism (version 6.00, GraphPad Software San Diego,
USA), using normalization and “log(inhibitor) vs. normalized
response – variable slope”.
In vitro tubulin polymerization
For tubulin polymerization experiments, A431 cells (2.5 × 105
cells per well) were grown overnight on (3-aminopropyl)-
triethoxysilane coated coverslips in 24-well plates and sub-
sequently incubated with 100 nM PTX, dPGS amine (1),
dPGS-PTX (3), dPG-PTX (4) for 16 h. After incubation, cells
were rinsed with PBS, fixated with 4% formaldehyde for 8 min,
and stored overnight in 0.1% formaldehyde. After rinsing, the
cells were permeabilized with 0.5% Triton X-100/PBS (4 min)
and blocked with a sterile filtered Milk/PBS-solution. Primary
monoclonal anti-α-tubulin-AB (Sigma-Aldrich. 1 : 4000 in dry
milk) was incubated for 1 h at rt, followed by rinsing and incu-
bation of secondary Cy™3-conjugated AﬃniPure donkey anti-
mouse antibody (Jackson ImmunoResearch. 1 : 200 in Milk;
1 h at rt). After nuclear counterstaining with 4′,6-diamidino-2-
phenylindole (DAPI; Carl Roth. 1 : 500 in PBS, 15 min), the
slides were mounted in fluorescent mounting medium (Dako).
Analysis of PTX release by HPLC
The study of the release of PTX from the conjugates dPGS-PTX
(3) and dPG-PTX (4) in human plasma, pH 7.4, pH 5.0, and pH
2.0 was carried out using a Knauer Smartline-HPLC system
with an internal UV absorption detector (λ = 227 nm) and
GeminyxSystem software. A Hypersil™ ODS C18 column
(Thermo Scientific, 100 mm × 4.6 mm, particle Size: 5 µm)
with a direct-connect guard column C18 was employed. Aceto-
nitrile–water (55 : 45) was used as the mobile phase at a flow
rate of 1.0 mL min−1 under isocratic regime. The injection
volume was 20 μL and each measurement was performed in
triplicate. Stock solutions of PTX in acetonitrile were prepared
and assessed by reverse phase HPLC (RP-HPLC) in order to
obtain a calibration curve for PTX (0.5–5 µg, R = 0.999) (Reten-
tion time: 2.9 min, Fig. S3, ESI†). dPGS-PTX (3) was incubated
at a constant PTX concentration of 0.8 mg mL−1 in human
plasma (1/3 diluted with PBS), or universal Britton–Robinson
buﬀer47 (BRB) at pH 7.4, 5.0 and 2.0. Samples were maintained
at 37 °C under continuous shaking, and aliquots (40 µL) were
taken at diﬀerent time intervals (1, 2, 3.5, 19 and 44 h). The
aqueous aliquots were mixed with 320 µL of Et2O–CHCl3
(1 : 1), vortexed for 2 min, and the phases were separated by
centrifugation (10 min, 10 000 rpm, rt). 150 µL of the organic
phase were taken for each sample, concentrated under
vacuum, reconstituted with 90 µL of acetonitrile and analyzed
by RP-HPLC. As control experiments, free PTX was incubated at
the same concentration, extracted under identical circum-
stances and then analyzed by RP-HPLC. Release experiments
were done thrice, and the release profile was corrected with the
mean recovery values obtained for the controls in each solution.
PTX extraction eﬃciency was in the range of 50–75%. In
addition, the release profile from dPGS-PTX (3) and dPG-PTX (4)
at diﬀerent pHs was compared. For that purpose, the conjugates
(constant PTX concentration) were incubated with BRB of pH
7.4, 5.0, and 2.0. Aliquots (40 µL) at diﬀerent time intervals were
taken, freeze-dried, redissolved in acetonitrile, and analyzed by
RP-HPLC. In this case, as no liquid–liquid extraction was
needed, control experiments were not necessary.
Results and discussion
Synthesis of the conjugates
dPGS was selected as the dendritic platform for conjugation to
PTX due to its non-toxicity, excellent inflammation-targeting
properties, and easy availability with functional groups.38
dPGS amine (1) (Scheme 1) was prepared from dPG following a
sequential synthetic strategy recently reported by our group.46
This approach involves partial mesylation of dPG OH groups,
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substitution of the mesyl groups with azides by treatment with
NaN3, sulfation of the remaining OH groups in the presence of
SO3 pyridine complex and, finally, reduction of the N3 groups
with TCEP under aqueous conditions. This methodology
allowed the synthesis of a large amount of dPGS amine (1) in
high purity and yield. Elemental analysis of dPGS amine (1)
showed a 80% degree of sulfation, while 1H NMR measure-
ments revealed a 15% of free amino functionalities available
for further conjugation.
To evaluate the ability of dPGS to eﬃciently internalize and
release PTX into cancer cells, we selected a pH-labile ester
linkage for the conjugation of the drug to dendritic platform.
This strategy should enable a controlled release through ester
hydrolysis in tumor tissues (pH ≈ 6) or after internalization in
the acidic cellular compartments endosomes/lysosomes (pH ≈
5.5–5). Ester linkages can also be degraded by the action of
hydrolytic enzymes. To this aim, PTX was reacted with succinic
anhydride and the resulting product was linked to NHS in the
presence of the coupling agent DCC to yield activated PTX-
Suc-NHS (2) (Scheme 1). The product was characterized by
ESI-MS, 13C and 1H NMR, which showed the expected peaks at
2.5, 2.6, and 2.7 ppm corresponding to the succinimide-NHS
protons. Likewise, the perfect match between experimental
and calculated m/z values confirmed the identity and the
purity of the compound (Fig. S1, ESI†). The coupling of com-
pounds 2 to and 1 had to be accomplished in a mixture of
DMF–H2O (9 : 1), because dPGS amine is only soluble in water
or aqueous mixtures and PTX is completely insoluble in water.
The synthesized conjugate was purified by dialysis in acetone
and water to remove unreacted PTX-Suc-NHS ester. As
expected, the conjugate dPGS-PTX (3) was water soluble, which
overcame the need for a surfactant, such as Cremophor EL®,
currently used to solubilize PTX in a therapeutic formulation.
The amount of PTX present in the conjugate could not be
determined by UV absorption at 227 nm, as typically done for
PTX-polymer conjugates, because the dendritic scaﬀold pre-
sented absorption in that region as well. Furthermore, 1H
NMR quantification could not be performed for diﬀerent
aqueous mixtures (D2O had to be present in order to solve
dPGS-PTX) because the HOD peak overlapped with the corres-
ponding protons in the dPGS amine scaﬀold. This matter was
finally solved by shifting the HOD peak by adding DCl (1.5%)
to a mixture of DMSO-d6 and D2O immediately before recording
the 1H NMR spectrum. This way, the amount of PTX present in
the conjugate could be determined by integration of the dPGS
amine and PTX signals in the 1H NMR spectrum (Fig. S2, ESI†).
The molar ratio PTX/dPGS was found to be approx. 1.4, which
represented a PTX average loading of 8.45% (weight PTX/weight
conjugate). The purity of the conjugate could also be deter-
mined by RP-HPLC, which showed a well-defined, single peak
and no signs of free drug (Fig. S3 (b), ESI†).
In order to analyze the eﬀect of the peripheral sulfate
groups of the conjugate on its cellular uptake and PTX cyto-
toxic activity, hydroxyl-terminated dPG was conjugated to the
drug following the same synthetic approach and was employed
as a non-sulfated control (4, Scheme 1). The lack of sulfate
groups in the control conjugate 4 extremely facilitated the
characterization of the final compound, because the conjugate
was completely soluble in common polar organic solvents
such as DMSO (Fig. S4, ESI†).
Finally, the peripheral amine groups displayed on these
structures allowed an easy simultaneous incorporation of PTX
and ICC dyes, which aﬀorded multifunctional platforms for
drug delivery. Labeling of 3 and 4 was accomplished by a
straightforward coupling of the remaining amine groups with
ICC-NHS ester. The incorporation of 0.2 ICC molecules on
average, as determined by UV absorbance, resulted in multi-
functional dendritic-drug structures 5 and 6 that could be
monitored by fluorescence microscopy. Importantly, previous
studies from our group have demonstrated that ICC dye conju-
gation does not have any significant influence on the target
aﬃnity of dPGS towards L-selectin.41
Scheme 1 Synthesis of dPGS-PTX-ICC (5) and schematic representation of non-sulfated controls 4 and 6.
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The quantitative cellular uptake of the conjugates
dPGS-PTX-ICC (5) and dPG-PTX-ICC (6) was studied using flow
cytometry in A431 cells. In addition, in order to perform a
comparison of the uptake kinetics of the drug and the dendri-
tic platform, PTX and dPGS amine (1) were labeled with the
same ICC dye [PTX-ICC (8) and dPGS-ICC (7), respectively].
Since dPGS-PTX-ICC (5) was envisioned as a potential drug
delivery platform for in vivo situations, the uptake analysis was
extended to 48 h. As shown in Fig. 2, PTX-ICC (8) and the
anionic conjugates dPGS-ICC (7) and dPGS-PTX-ICC (5)
showed a strong internalization at 12 h, while neutral
dPG-PTX-ICC (6) had a comparable response to the negative
control (medium).
A strong diﬀerence was also observed for the internalization
kinetics of the various compounds. The analysis of the
PTX-ICC (8) internalization revealed a logarithmic uptake
kinetic with a saturation plateau, while dPGS-PTX-ICC (5) was
taken up linearly without any saturation plateau over 48 h
(Fig. 3). This indicates a non-saturated transport of the conju-
gate. Notably, the observed logarithmic uptake for PTX was
much slower than what has been described in the literature.48
The diﬀerent behaviors might be attributed to the conjugation
of PTX to the ICC moiety. Interestingly, as seen in Fig. 3, the
lack of PTX in dPGS-ICC (7) resulted in a completely diﬀerent
uptake profile. This can be explained by the strong decrease in
the hydrophobicity of this conjugate along with the absence of
the active PTX fraction (ongoing proliferation). Remarkably, in
concordance with previous results,37 only a minor uptake of
dPG-PTX-ICC (6) was observed after several hours, confirming
that cellular uptake is strongly charge and size dependent.49
Our group has previously shown that neutral dPG was not
uptaken by diﬀerent cell lines when the molecular weights
were below 20 kDa, while dPGS with similar molecular weights
was rapidly internalized in those cells.37,41,49 Besides flow cyto-
metry, fluorescence microscopy was also employed to monitor
the internalization of dPGS-PTX-ICC (5) in A431 cells. Accord-
ing to microscopic analysis, dPGS-PTX-ICC (5) was predomi-
nantly localized in the surrounding of cell nuclei and
displayed increasing fluorescence during the incubation
period, which indicated cellular accumulation of the conjugate
(Fig. S5, ESI†).
Elimination kinetics revealed a prolonged fluorescence of
dPGS-PTX-ICC (5) in A431 cells compared to drug-free
dPGS-ICC (7), indicating a slow release and intracellular
accumulation of dPGS-PTX-ICC (5) (Fig. S6, ESI†). This
accumulation profile seems to be ideal for the delivery of cyto-
toxic agents whose eﬀects are cell cycle- or time-dependent.
We hypothesize that this observation might be due to the pres-
ence of the active agent PTX, which reduces the proliferation
and therefore the distribution of fluorescence to posterior
generations.
In vitro cytotoxicity in A549 and A431 cells
In vitro toxicity was assessed in A549 and A431 cell lines. A549
cell line was selected because PTX is a chemotherapeutic agent
commonly used for the treatment of lung carcinoma. A549
cells represent a human adenocarcinoma of the lung with
typical features of pneumocytes type II. On the other hand,
A431 cells are derived from a squamous cell carcinoma and
highly express EGF-receptors. As shown in Fig. 4, free PTX was
more toxic than dPGS-PTX (3) in both cell lines. dPGS-PTX (3)
presented higher IC50 values (related to the PTX equivalents)
than free PTX for each time point measured (Fig. 4 and
Table S1 in ESI†). This is a typical observation when a free
drug, which enters cells by diﬀusion, is compared to a multi-
functionalized polymer-drug conjugate that is taken up by
endocytosis.50,51 Specifically, at 48 h, IC50 values of dPGS-PTX
Fig. 2 Representative distribution of A431 cells in FL2-H histograms. (a)
Incubation time = 12 h, (b) incubation time = 48 h.
Fig. 3 Internalization kinetic proﬁles of PTX-ICC (8), dPGS-ICC (7),
dPGS-PTX-ICC (5) and dPG-PTX-ICC (6) in A431 cells (concentration =
1 μM).
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(3) were 7.6 nM for A431 cells, which is about 2.3-fold higher
than that of free PTX. In the case of dPG-PTX (4), IC50 values
were 1.5-fold higher than that of dPGS-PTX (3). The obtained
IC50 values of PTX in A549 cells fit with those described in the
literature,52–56 while the published IC50 values of A431 diﬀered
between the sources57–59 and those presented here. The con-
centration-response curves obtained for both PTX and the con-
jugate were nevertheless conclusive (Fig. 4). In addition,
experiments performed with dPGS amine (1) showed that
there is no reduced viability of A431 cells after 48 h of incu-
bation (IC50 value not evaluable; Fig. S7, ESI†). This is consist-
ent with previous reports37 and confirms that the cytotoxic
eﬀect is related to the PTX fraction of the conjugate.
In vitro activity of PTX and dPGS-PTX conjugates in A431 cells
The in vitro activity of the conjugates towards tubulin polymer-
ization was studied by confocal microscopy. Fig. 5 shows repre-
sentative confocal microscopy images of tubulin aggregation
and reduction of free cytosolic tubulin staining induced by
PTX and by dPGS-PTX (3). Treatment with the nude dendritic
platform dPGS amine (1) did not cause tubulin aggregation.
However, when the activity of control conjugate dPG-PTX (4)
was analyzed, it was seen that the non-sulfated conjugate
induced aggregation of tubulin to a similar extent as the
activity observed for PTX and dPGS-PTX (3). Cell viability
measurements were in concordance with these observations.
This type of activity was not expected for the neutral conjugate,
because dPG-PTX (4) was marginally internalized by A431
cells, as clearly demonstrated in the above sections. One plaus-
ible explanation for these findings could be the hydrolysis of
the ester linkage, which would result in a premature PTX
release from the conjugates before they were internalized in
the cells. This hypothesis would explain the similar activity of
PTX found in both conjugates, since the free PTX would enter
the cells regardless of the nanocarrier. To further demonstrate
this data interpretation, we analyzed the release of the drug
from both conjugates at diﬀerent pHs and in the presence of
esterases and other hydrolytic enzymes (human plasma).
Study of the release of PTX from dPGS-PTX (3) and dPG-PTX
(4) by HPLC
In order to better understand the results obtained in the ana-
lysis of the activity towards tubulin polymerization induced by
both sulfated and non-sulfated conjugates, we decided to
study the release profile of PTX from the conjugate dPGS-PTX
(3) at diﬀerent pHs and in human plasma. We aimed to evalu-
ate the stability of the ester linkage in the presence of esterases
and other endogenous hydrolytic enzymes present in plasma.
For that purpose, a liquid-liquid extraction protocol was
chosen to isolate free PTX from dPGS and plasma proteins.
Control experiments with known concentrations of the free
drug were performed in order to validate the method and
establish the extraction eﬃciency. PTX was stable during the
time of analysis, and no degradation products were observed.
The obtained release profile at 37 °C over a 44 h period is
shown in Fig. 6. It can be clearly observed that the PTX release
in human plasma is extremely fast, with values of 75% of PTX
release within 3.5 h. These observations are in concordance
with our premature drug release hypothesis and would explain
the results obtained for tubulin polymerization. Indeed, the
hydrolysis rate of the ester bond was much higher in buﬀer at
pH 7.4 (85% at 24 h) than in pH 5 (15% at 24 h). This behavior
has been reported for other polymer-PTX conjugates26,28 and
is expected for succinimidyl esters hydrolysis.60 Nevertheless,
in the case of neutral dPG-PTX (4) we did not observe such an
eﬀect, and PTX release was higher at acid pH (only 15% of
release in buﬀer at pH 7.4 at 24 h). PTX release via succini-
midyl ester hydrolysis from other dendritic scaﬀolds has been
previously studied, with absolutely diﬀerent results. Thus, in
the case of hydroxyl-terminated poly(amido amine) PAMAM
conjugated to PTX, only 20% of free drug was observed after
24 h of incubation in the presence of esterases,24 for hyal-
uronic acid-PTX conjugates, approx. 40% of the drug was
released at 24 h,27 while a 100% release in the same time inter-
val was reported for dendritic poly(ethylene glycol) bearing PTX
and alendronate.28 In addition, the supramolecular organization
of the conjugates in solution, i.e., the formation of micelles or
supramolecular aggregates, is known to significantly aﬀect the
drug release kinetics.28 These diverse PTX release profiles
Fig. 4 Concentration-response curve of PTX and dPGS-PTX (3) incu-
bated on A549 and A431 cells at diﬀerent time intervals. dPGS-PTX (3)
conjugates present higher IC50-values compared to free PTX at every
measurement point.
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suggest that the employment of ester linkages for the covalent
attachment of PTX or other cytotoxic drugs to polymeric plat-
forms should be carefully evaluated for each particular system.
Conclusions
In this paper we describe the synthesis and characterization of
multifunctional dendritic conjugates for the delivery of PTX.
dPGS was chosen as the dendritic platform based on its excel-
lent inflammation targeting properties and was conjugated to
PTX through a succinyl ester linkage. Hydroxyl-terminated
dPG-PTX conjugates were prepared as non-targeting controls,
and both conjugates were further functionalized with an ICC
dye. Cellular uptake experiments showed that anionic
dPGS-PTX-ICC was rapidly internalized into A431 cells, while
the uptake of dPG-PTX-ICC was only marginal. However, both
conjugates generated the same activity towards tubulin
polymerization. Their similar toxic profile could be explained
by a premature drug release by the action of hydrolytic
enzymes, as demonstrated by HPLC. Our results suggest that
information on the kinetics of the release is critical for design-
ing polymer-drug conjugates and must be carefully evaluated
for each particular case. We are currently focusing on a
diﬀerent linker to improve the therapeutic properties of this
conjugate. Nevertheless, the multifunctional conjugates
described herein may find application in processes where a
fast drug release is required.
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Fig. 6 Cumulative release (in %) of PTX from dPGS-PTX (3) at 37 °C in
human plasma and at diﬀerent pH buﬀers.
Fig. 5 Representative confocal microscopy images of A431 cells incubated with (a) media, (b) PTX, (c) dPGS-PTX (3), (e) dPGS amine (1), and (f )
dPG-PTX (4). (d) Represents a negative control. PTX, dPGS-PTX (3) and dPG-PTX (4) promote histologically visible tubulin alteration. dPGS amine (1)
does not inﬂuence tubulin. C = 100 nM, incubation time = 16 h. Immunocytochemical staining of α-tubulin (green) and nuclear staining with DAPI
(blue). Mitosis is seen in (a).
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